Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R
Institute of Clinical Pathology, University of Vienna, Austria.
Cancer Res. 1990 Nov 1;50(21):7057-61.
An immunocytochemical assay (ICA) for the measurement of estrogen receptor (ER) and progesterone receptor (PgR) has been evaluated in 426 human primary breast carcinomas. For estrogen receptor determination ER ICA was used. PgR ICA was performed using the monoclonal antibody KD 68. Assay results for progesterone receptor immunocytochemistry were in agreement (P less than 0.0001) with those of biochemical determination in 74%. Progesterone receptor positivity determined with a semiquantified approach based on intensity and heterogeneity of immunocytochemical staining correlated significantly with biochemically determined progesterone receptor levels (P = 0.0001). Survival data showed a significantly better overall survival for patients with either ER ICA- or PgR ICA-positive carcinomas (ER ICA, P less than 0.00001; PgR ICA, P = 0.004). Patients with both negative ER ICA and PgR ICA showed a poorer prognosis than patients with only one negative receptor. In ER ICA- and PgR ICA-positive carcinomas a trend could be found that patients whose carcinomas contained high numbers of receptor-positive tumor cells had a better survival. This study demonstrates that ER ICA and PgR ICA are strong prognostic indicators and that the proportion of steroid hormone receptor-positive tumor cells seems to be of clinical importance.
对426例原发性人类乳腺癌进行了一项用于检测雌激素受体（ER）和孕激素受体（PgR）的免疫细胞化学分析（ICA）。雌激素受体检测采用ER ICA。PgR ICA使用单克隆抗体KD 68进行。孕激素受体免疫细胞化学分析结果与生化检测结果一致（P<0.0001）的比例为74%。基于免疫细胞化学染色强度和异质性的半定量方法确定的孕激素受体阳性与生化测定的孕激素受体水平显著相关（P = 0.0001）。生存数据显示，ER ICA或PgR ICA阳性癌症患者的总生存率显著更高（ER ICA，P<0.00001；PgR ICA，P = 0.004）。ER ICA和PgR ICA均为阴性的患者预后比仅有一种受体阴性的患者更差。在ER ICA和PgR ICA阳性的癌症中，可以发现一个趋势，即癌症中含有大量受体阳性肿瘤细胞的患者生存率更高。本研究表明，ER ICA和PgR ICA是强有力的预后指标，类固醇激素受体阳性肿瘤细胞的比例似乎具有临床重要性。
